Borneol/edaravone - Simcere

Drug Profile

Borneol/edaravone - Simcere

Alternative Names: Compound edaravone; Edaravone combination; Edaravone/borneol; SIM 071201

Latest Information Update: 27 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Class Heterocyclic bicyclo compounds; Neuroprotectants; Pyrazolones; Small molecules; Terpenes
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stroke
  • No development reported Cerebrovascular disorders

Most Recent Events

  • 01 Dec 2016 Jiangsu Simcere completes a phase-III trial in Stroke in China (Parenteral) (NCT02430350)
  • 05 Oct 2015 No recent reports on development identified - Phase-I for Cerebrovascular disorders (In volunteers) in Australia (Parenteral)
  • 01 May 2015 Phase-III clinical trials in Stroke in China (Parenteral) (NCT02430350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top